The first full week of November delivers a broad and high-impact earnings lineup across semiconductors, cloud software, AI, consumer retail, healthcare, cannabis, energy, media, and crypto-linked ...

Pfizer has beaten its earnings per share (EPS) estimates in its past 12 quarters. Beating EPS estimates hasn't always meant positive movements for Pfizer's share price. The stock's low valuation and ...

Pfizer ($PFE) has reached a deal to buy Metsera ($MTSR), a weight-loss drug startup, in a transaction that could total more ...

FAA to reduce air traffic by 10% across 40 'high-volume' markets. Pfizer matches Novo bid for obesity Metsera as takeover ...

The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always ...

Pfizer stock (NYSE: PFE) has recently announced its Q1 results, reporting revenues that fell short of expectations while earnings surpassed analyst predictions. The company disclosed revenue of $13.7 ...

Pfizer Inc. (NYSE:PFE) is one of the top low volatility healthcare stocks to buy now. On July 22, Morgan Stanley analyst Terence Flynn maintained a Hold rating on Pfizer Inc. (NYSE:PFE) and set a ...

Pfizer crushed Q2 estimates with $14.7B revenue and $0.78 EPS, signaling a powerful turnaround driven by broad-based growth and operational excellence. A successful cost realignment program drove the ...